GM-CSF: Clinical Trials

11 trials of GM-CSF, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 active not recruiting, 1 unknown, 1 withdrawn. 11 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 311Completed 8, Active not recruiting 1, Unknown 1, Withdrawn 1

Follow GM-CSF: new trials by email Literature Review of GM-CSF trials Research Report on GM-CSF

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
GM-CSF, Placebo - Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
Phase 3CompletedNationwide Children's Hospital1412022-06-142026-04-09
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Galinpepimut-S, Azacitidine, Venetoclax - Acute Myeloid Leukemia
Phase 3Active not recruitingSellas Life Sciences Group1272021-02-082025-10-01
Use of GM-CSF Treatment in Recurrent Implantation Failure
GM-CSF group, CONTROL - Women With Recurrent Implantation Failure in IVF
Phase 3UnknownCentre for Endocrinology and Reproductive Medicine, Italy1402017-12-122022-07-20
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
PROSTVAC-V, PROSTVAC-F, GM-CSF - Prostate Cancer Metastatic
Phase 3CompletedBavarian Nordic12972011-11-282019-09-04
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
sargramostim, sentinel lymph node biopsy, laboratory biomarker analysis - Stage IB Melanoma, Stage IIA Melanoma
Phase 3WithdrawnJonsson Comprehensive Cancer Center2011-08-052020-07-27
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Sunitinib, GM-CSF, Cyclophosphamide - Metastatic Renal Cell Carcinoma
Phase 3CompletedImmatics Biotechnologies GmbH3392010-12-012017-10-12
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
Talimogene laherparepvec, GM-CSF - Melanoma
Phase 3CompletedBioVex Limited4372009-04-012016-07-13
Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma
dactinomycin, vincristine sulfate, cyclophosphamide - Adult Malignant Mesenchymoma, Adult Rhabdomyosarcoma
Phase 3CompletedChildren's Oncology Group7022002-09-012013-06-17
Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)
GM-CSF - Acute Myeloid Leukemia
Phase 3CompletedAcute Leukemia French Association4731999-03-012009-04-13
Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
Myeloma Immunoglobulin Idiotype Vaccine-KLH, GM-CSF - Graft vs Host Disease, Multiple Myeloma
Phase 3CompletedNational Cancer Institute (NCI)301996-11-012007-09-24
Combination Chemotherapy in Treating Children With Neuroblastoma
filgrastim, sargramostim, carboplatin - Neuroblastoma
Phase 3CompletedChildren's Oncology Group5731988-03-012014-08-01

Conditions studied

Leukemia, Myeloid, Acute (2)  ·  Melanoma (2)  ·  Carcinoma, Renal Cell (1)  ·  Graft vs Host Disease (1)  ·  Malignant mesenchymal tumor (1)  ·  Multiple Myeloma (1)  ·  Neoplasm Metastasis (1)  ·  Neuroblastoma (1)  ·  Pathologic Complete Response (1)  ·  Prostatic Neoplasms (1)  ·  Rhabdomyosarcoma (1)  ·  Sarcoma (1)

Sponsors

Children's Oncology Group (2)  ·  Acute Leukemia French Association (1)  ·  Bavarian Nordic (1)  ·  BioVex Limited (1)  ·  Centre for Endocrinology and Reproductive Medicine, Italy (1)  ·  Immatics Biotechnologies GmbH (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  Nationwide Children's Hospital (1)  ·  Sellas Life Sciences Group (1)

Countries

United States (9)  ·  Canada (3)  ·  France (3)  ·  Germany (3)  ·  Netherlands (3)  ·  Poland (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Hungary (2)  ·  Italy (2)  ·  Puerto Rico (2)  ·  Russia (2)  ·  Spain (2)  ·  Belgium (1)  ·  Denmark (1)

Top investigators

Brian Rini, MD (1)  ·  Carola Arndt (1)  ·  David L. Baker, MD, MBBS, FRACP, FRCPA (1)  ·  James L. Gulley, MD (1)  ·  Marco Sbracia, MD (1)  ·  Philip Kantoff, MD (1)  ·  Richard Essner (1)  ·  Tim Eisen, MD (1)

Results publications

PMID 17252021, PMID 20625116, PMID 20879880, PMID 21690555, PMID 26014293, PMID 27720136, PMID 28923101, PMID 30817251, PMID 31171039, PMID 37498156, PMID 38603649, PMID 39606837, PMID 40965804

NIH funding

2008 (1), R01CA120228 (1), U10CA098543 (1)